List of Excipients in Branded Drug KETAMINE HYDROCHLORIDE

Generic Drugs Containing KETAMINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	ketamine hydrochloride	0143-9508	BENZETHONIUM CHLORIDE
Henry Schein Inc	ketamine hydrochloride	0404-9881	BENZETHONIUM CHLORIDE
Henry Schein Inc	ketamine hydrochloride	0404-9882	BENZETHONIUM CHLORIDE
Hospira Inc	ketamine hydrochloride	0409-0040	BENZETHONIUM CHLORIDE
Hospira Inc	ketamine hydrochloride	0409-2051	BENZETHONIUM CHLORIDE
Hospira Inc	ketamine hydrochloride	0409-2051	WATER

What are the Most Frequently-Used Excipients in KETAMINE HYDROCHLORIDE?

# Of NDCs	Excipient
19	BENZETHONIUM CHLORIDE
6	SODIUM CHLORIDE
4	WATER

Ketamine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Ketamine hydrochloride is a low-cost, off-patent active pharmaceutical ingredient with limited opportunity in conventional injectable products and greater opportunity in differentiated delivery systems. The strongest commercial strategies are preservative-free specialty injectables, intranasal and transmucosal products, abuse-deterrent formulations, controlled-release systems, and formulations optimized for outpatient psychiatric or pain use.

The core commercial constraint is regulatory rather than chemical. Ketamine hydrochloride is an FDA-approved injectable anesthetic and Schedule III controlled substance, while chronic pain, depression, and other emerging uses generally require a new drug application, a 505(b)(2) pathway, or use under physician discretion outside the approved label. Esketamine nasal spray, marketed as Spravato, is a separate product with its own clinical, regulatory, patent, and reimbursement profile. [1-4]

What is the FDA regulatory status of ketamine hydrochloride?

Ketamine hydrochloride injection is approved in the United States for induction and maintenance of general anesthesia. FDA-approved products are primarily intravenous or intramuscular injections containing ketamine hydrochloride in aqueous solution. [1]

Attribute	Ketamine hydrochloride
Active ingredient	Ketamine hydrochloride
Therapeutic class	Dissociative anesthetic; NMDA receptor antagonist
Common dosage forms	IV and IM injection
FDA-approved U.S. use	Induction and maintenance of general anesthesia
Controlled-substance status	Schedule III
Chemical entity patent status	Long expired
Primary FDA pathways for new products	ANDA, 505(b)(2), or NDA
Established pharmaceutical advantage	High aqueous solubility and rapid parenteral exposure
Main formulation risks	Preservative toxicity, pH control, dose uniformity, abuse potential, stability, and route-specific tolerability

Ketamine hydrochloride is a racemic mixture of R-ketamine and S-ketamine. The approved injection products do not rely on an excipient-based extension of the original compound patent. Commercial differentiation must come from dosage form, administration route, pharmacokinetics, safety, convenience, manufacturing quality, or a defined clinical indication.

What excipients are used in ketamine hydrochloride injection?

The simplest ketamine hydrochloride formulation uses water for injection and sodium chloride for isotonicity. Some multidose or preserved presentations include a preservative, while preservative-free presentations are preferred when repeated exposure or vulnerable patient populations create a safety concern. Product-specific inactive ingredients must be confirmed against the applicable FDA label and DailyMed record. [1,5]

Conventional injectable excipient architecture

Formulation component	Commercial function	Key considerations
Water for injection	Solvent	Must meet parenteral quality requirements
Sodium chloride	Tonicity adjustment	Supports isotonic or near-isotonic administration
Hydrochloride salt form	Solubility and pH control	Enables a concentrated aqueous solution
Benzethonium chloride or other preservative, where applicable	Multidose microbial protection	Requires route, concentration, toxicology, and labeling assessment
pH adjuster	Maintains chemical stability and tolerability	Excessive acidity can increase injection-site discomfort
Nitrogen or controlled headspace, where used	Oxidation control	Relevant to oxygen-sensitive formulations and container closure design

Ketamine hydrochloride is particularly suitable for aqueous dosage forms because the salt is water soluble. The formulation challenge is therefore not primarily solubilization. It is achieving acceptable pH, preservative safety, container compatibility, sterilization robustness, and dose flexibility.

Preservative-free versus preserved ketamine injection

Preservative-free single-dose vials have the clearest hospital and specialty-care value. They can be positioned for operating rooms, emergency departments, procedural sedation, pediatric use, and repeated low-dose administration where preservative exposure is undesirable.

Preserved multidose vials can reduce packaging and handling costs but create a narrower clinical positioning. The preservative must be assessed for neurotoxicity, local tolerability, compatibility with the intended route, and suitability for neuraxial or other specialized administration. A formulation approved for IV or IM use should not be promoted for epidural, intrathecal, or other routes without route-specific regulatory support.

What formulation patents could protect ketamine hydrochloride products?

The original ketamine molecule and basic ketamine hydrochloride injectable formulation are not credible sources of new composition-of-matter exclusivity. New protection would need to focus on formulation, device, manufacturing, pharmacokinetics, or a defined method of use.

Potential patentable claim categories

Claim category	Potential protected subject matter	Commercial value
Intranasal formulation	Concentration, pH, osmolarity, buffer system, viscosity modifier, mucoadhesive, preservative system	High if linked to improved exposure or usability
Oral or buccal formulation	Taste masking, permeation enhancement, dosage uniformity, solid dispersion, film or lozenge architecture	Moderate to high, but clinical and abuse risks are substantial
Controlled release	Injectable depot, biodegradable microparticle, implant, in situ gel, or long-acting matrix	High if the product reduces dosing frequency without unacceptable psychotomimetic effects
Abuse deterrence	Aversion agent, antagonist combination, tamper-resistant package, controlled delivery rate	Potentially high, although clinical validation is demanding
Device combination	Metered nasal spray, dose counter, locked delivery system, tamper evidence	Moderate to high when device performance is clinically meaningful
Manufacturing	Crystallization, impurity control, sterilization, container closure, particulate reduction	Moderate; strongest when it solves a recognized quality problem
Method of use	Dosing regimen, patient selection, combination therapy, anesthesia or pain protocol	Variable and dependent on clinical differentiation
Combination product	Ketamine plus local anesthetic, antidepressant, antiemetic, or other active ingredient	Potentially high, but requires compatibility and clinical evidence

A patent claim covering only “ketamine in a pharmaceutical composition” is vulnerable because the active ingredient and many conventional excipients are old. Stronger claims should define a measurable technical result, such as a specified pharmacokinetic profile, reduced spray-to-spray variability, improved storage stability, reduced preservative exposure, or a controlled release interval.

What excipient strategy is strongest for intranasal ketamine?

Intranasal delivery is the most commercially credible noninjectable opportunity, but the product must be distinguished from esketamine rather than treated as a simple generic substitute. Spravato contains esketamine hydrochloride and is approved for treatment-resistant depression and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, subject to a restricted distribution and monitoring program. [2]

A racemic ketamine nasal product would need to address:

• Dose uniformity across repeated actuations.
• Nasal residence time.
• Local irritation and burning.
• pH and osmolarity.
• Microbial preservation.
• Absorption variability caused by congestion, rhinitis, and mucosal condition.
• Abuse and diversion risk.
• Systemic exposure to both enantiomers.
• Clinical positioning relative to Spravato and compounded ketamine.

Candidate intranasal excipient classes

Excipient class	Purpose	Development risk
Citrate, phosphate, or related buffer	pH control	Nasal irritation and buffer capacity must be assessed
Sodium chloride or other tonicity agent	Osmolarity adjustment	Excessive tonicity can worsen discomfort
Hydroxypropyl methylcellulose or similar polymer	Increased residence time	Can affect spray plume and dose delivery
Mucoadhesive polymer	Improved nasal retention	May reduce reproducibility or increase irritation
Surfactant	Wetting or dispersion support	Often unnecessary for a highly water-soluble salt; may irritate mucosa
Preservative	Multidose microbial protection	Requires route-specific safety assessment
Chelating agent	Metal-ion control and stability	May affect compatibility and regulatory acceptability
Taste-modifying system	Reduced postnasal drip unpleasantness	Must not impair absorption or spray performance

The preferred design is generally a low-excipient aqueous spray with tight pH and osmolality control. More excipients do not necessarily create stronger intellectual property. A technically simple formulation with validated dose delivery, lower irritation, and a reliable device may have greater commercial value than a complex formulation with weak clinical differentiation.

What commercial opportunities exist for ketamine hydrochloride?

1. Specialty injectable supply

The lowest-risk opportunity is a high-quality injectable product with supply, packaging, or handling advantages. Potential differentiators include:

• Preservative-free single-dose vials.
• Ready-to-use diluted bags or syringes.
• Multiple concentrations for anesthesia and procedural sedation.
• Low-sorption container systems.
• Improved labeling and barcode integration.
• Smaller vial sizes for ambulatory and office-based use.
• Reliable shortage-resistant manufacturing.

This market is competitive and price-sensitive. A standard injectable product is more likely to generate volume than durable pricing power.

2. 505(b)(2) intranasal ketamine

A sponsor could pursue racemic ketamine nasal spray under an NDA or 505(b)(2) application, depending on the reference product and reliance strategy. The commercial opportunity depends on demonstrating an indication, dosing regimen, or product attribute not adequately addressed by existing products.

Potential target settings include monitored outpatient administration, perioperative analgesia, treatment-resistant psychiatric disorders, and acute pain. Each setting has different clinical endpoints, abuse controls, and reimbursement requirements.

3. Buccal, sublingual, or oral dosage forms

Buccal films, sublingual tablets, lozenges, and oral capsules could improve patient convenience and eliminate injection equipment. The principal formulation problems are taste, dose uniformity, variable absorption, and first-pass metabolism.

A successful product would need a clear reason to exist beyond compounded formulations. Possible differentiators include:

• Standardized dose delivery.
• Lower exposure variability.
• Reduced swallowing and gastrointestinal exposure.
• Tamper-resistant packaging.
• Lower peak concentration to reduce dissociation and hemodynamic effects.
• A clinically validated dosing schedule.

Because ketamine has abuse potential, a take-home oral product would face a more demanding risk-management and diversion analysis than a clinic-administered injection.

4. Long-acting ketamine formulations

Depot injections, biodegradable microspheres, implants, and in situ gels could reduce dosing frequency. This approach has the largest theoretical product value but also the highest technical and clinical risk.

A controlled-release ketamine product must manage:

• Initial burst release.
• Dose dumping.
• Long-term local tolerability.
• Reversibility if adverse neuropsychiatric or cardiovascular effects occur.
• Release consistency across manufacturing lots.
• Accumulation after repeated doses.
• Recovery from excessive sedation or dissociation.

The commercial case is strongest for a product that produces a predictable exposure profile while reducing peak-related adverse effects. A depot product that cannot be rapidly discontinued may face significant clinical resistance.

When does ketamine hydrochloride lose exclusivity?

Ketamine hydrochloride’s basic compound and conventional injectable formulation are long off patent. FDA generic competition is therefore established for standard injectable presentations, subject to product availability and manufacturing capacity.

Exclusivity element	Status
Original ketamine compound patent	Expired
Basic ketamine hydrochloride injection claims	Generally expired or vulnerable to prior art
FDA approval of conventional injection	Established generic market
New formulation patents	Potentially available if claims are novel and nonobvious
New method-of-use patents	Potentially available, subject to written-description, enablement, and obviousness risks
Orphan exclusivity	Not inherent to ketamine; depends on a qualifying FDA designation and approval
Pediatric exclusivity	Product-specific; no automatic protection
Spravato exclusivity	Applies to esketamine nasal spray, not automatically to racemic ketamine

The relevant regulatory protection for a differentiated ketamine product may come from a combination of patent claims, clinical exclusivity, orphan designation, data exclusivity, device protection, and controlled-distribution infrastructure. None of these protections automatically extends to conventional ketamine hydrochloride injection.

What is the Orange Book status of ketamine hydrochloride?

The FDA Orange Book lists approved drug products and relevant patent and exclusivity information. Conventional ketamine hydrochloride injection products are generally generic injectable products rather than innovator products with meaningful remaining compound exclusivity. Orange Book status must be reviewed by product and strength because listings, approved manufacturers, and any patent certifications can change. [3]

A sponsor developing a new ketamine formulation should distinguish three situations:

1. An ANDA for a pharmaceutically equivalent injectable product.
2. A 505(b)(2) product that relies partly on existing ketamine safety or efficacy data but introduces a new route, formulation, device, or indication.
3. A full NDA for a novel clinical product requiring substantial independent evidence.

The presence of Spravato in the Orange Book does not create an automatic patent barrier for racemic ketamine hydrochloride. It can, however, affect freedom-to-operate analysis where a proposed product uses overlapping nasal-delivery, dosing, device, or treatment concepts.

Which companies are challenging ketamine exclusivity?

No single company challenge defines the conventional ketamine hydrochloride market because the active ingredient is already generic. Competition is distributed among injectable generic manufacturers, compounding pharmacies, specialty clinics, and developers of next-generation NMDA-antagonist products.

The more relevant competitive groups are:

• Generic injectable manufacturers supplying hospitals.
• Compounders producing non-FDA-approved ketamine dosage forms.
• Janssen and its commercial partners for esketamine nasal spray.
• Biopharmaceutical companies developing rapid-acting antidepressants and other NMDA-pathway products.
• Device and specialty-pharma companies developing nasal, buccal, or controlled-release platforms.

A Paragraph IV challenge is most relevant to a newly approved formulation or method-of-use patent, not to the original ketamine molecule. For a new product, the key litigation question would be whether an ANDA applicant can design around formulation or device claims while preserving pharmaceutical equivalence or therapeutic substitutability.

What patent litigation and settlement risks affect ketamine products?

Conventional ketamine injection has limited patent-litigation exposure because the central molecule and basic formulation are old. Litigation risk increases sharply for:

• Racemic ketamine nasal sprays positioned against esketamine.
• New dosing regimens for depression or pain.
• Device-enabled products.
• Long-acting formulations.
• Combination products.
• Products claiming reduced adverse effects through controlled exposure.

Potential disputes include patent validity, obviousness, written description, enablement, claim construction, induced infringement, and whether a proposed product falls within a listed method-of-use patent. Settlement agreements may include delayed launch dates, licenses, authorized-generic arrangements, manufacturing restrictions, or carve-outs for unpatented indications.

A practical diligence process should review Orange Book listings, FDA approval letters, USPTO file histories, Federal Court dockets, and any product-specific ANDA litigation. [3,6]

How strong is the patent estate for ketamine hydrochloride?

The patent estate is weak for conventional ketamine hydrochloride injection and potentially strong for a clinically differentiated delivery system.

Product strategy	Expected patent strength	Main reason
Standard aqueous IV/IM injection	Low	Mature API, old dosage form, extensive prior art
Preservative-free injection	Low to moderate	Manufacturing and package claims may exist, but composition claims are narrow
Intranasal racemic ketamine	Moderate	Route, device, formulation, and regimen claims can be differentiated
Buccal or sublingual product	Moderate	Absorption, taste masking, and dosage-form claims may support protection
Long-acting depot	Moderate to high	Complex release technology and clinical performance can create defensible claims
Abuse-deterrent product	Moderate	Requires demonstrated deterrence and credible nonobviousness
New method of use	Variable	Clinical differentiation is necessary; obviousness risk is material
Ketamine combination product	Moderate	Depends on unexpected efficacy, safety, or pharmacokinetic results

Patent value will depend on claim breadth and the ability to prevent substitution. A narrow formulation patent may be commercially weak if an ANDA or 505(b)(2) competitor can change the buffer, polymer, concentration, or device without losing clinical utility.

What manufacturing and intellectual-property barriers apply?

The API itself is not the primary barrier. The main barriers are product quality, sterile manufacturing, controlled-substance controls, and route-specific clinical evidence.

Key manufacturing barriers

• Sterile filling and aseptic processing.
• Particulate and endotoxin control.
• Container closure integrity.
• Compatibility with glass, elastomer, and polymer components.
• Preservative concentration control.
• Light and temperature stability.
• Accurate low-dose filling for psychiatric or analgesic applications.
• Nasal actuator reproducibility.
• Controlled-substance inventory, reconciliation, and security.
• Prevention of diversion from manufacturing through dispensing.

For an intranasal or oral product, the device and packaging system may be as important as the liquid formulation. Dose counters, tamper evidence, restricted dispensing, and unit-dose packaging can support both regulatory review and commercial positioning.

How does ketamine hydrochloride compare with esketamine?

Attribute	Ketamine hydrochloride	Esketamine
Molecular composition	Racemic mixture	S-enantiomer
Established U.S. dosage form	IV/IM injection	Nasal spray
FDA-approved psychiatric indication	No general depression approval	Yes, subject to labeling and monitoring
Conventional market	Generic injectable supply	Branded specialty product
Patent opportunity	New formulation, route, device, or use	Existing product-specific estate and regulatory protections
Administration setting	Hospital, procedural, or clinical use	Certified healthcare setting under restricted distribution
Commercial differentiation	Cost, formulation, delivery, and new indication	Approved indication, clinical infrastructure, and brand
Substitution risk	High for standard injection	Lower due to product-specific indication and administration requirements

The commercial opportunity is not to copy the pharmacology alone. A ketamine hydrochloride product must compete on dose control, clinical workflow, cost, patient selection, monitoring burden, or a different therapeutic use.

What generic launch scenarios exist for ketamine hydrochloride?

Standard injectable launch

This is the fastest and lowest-risk route if the product is pharmaceutically equivalent to an approved reference product. Expected pricing pressure is high, and market access depends on reliable supply, hospital contracting, and manufacturing performance.

Differentiated injectable launch

A preservative-free, ready-to-administer, prefilled, or concentration-specific product can seek hospital and ambulatory-care differentiation. The opportunity is commercial rather than molecule-based and may support limited formulation or process patents.

505(b)(2) nasal launch

A nasal product could seek approval based partly on existing ketamine data while generating new clinical evidence for the proposed formulation and indication. The principal risk is that the product may require a substantial clinical program if the pharmacokinetic, safety, or efficacy profile differs materially from established injection products.

Specialty psychiatric launch

A clinic-administered product could target treatment-resistant depression or related conditions. It would compete with Spravato, off-label compounded ketamine, and emerging rapid-acting antidepressants. Reimbursement and controlled administration may determine commercial success more than API cost.

What is the revenue exposure and commercial upside?

Revenue exposure is modest for undifferentiated ketamine injection because the product is generic and hospital purchasing is price-sensitive. The greater upside is in a differentiated formulation that captures a clinical workflow or reimbursement advantage.

Opportunity	Revenue profile	Principal risk
Commodity injection	Volume-driven, low margin	Price erosion and supply competition
Premium preservative-free injection	Moderate margin	Limited differentiation and hospital substitution
Ready-to-use or prefilled injection	Moderate margin	Device, stability, and packaging costs
Intranasal ketamine	Potentially high	Clinical evidence, abuse controls, and competition with Spravato
Buccal or sublingual product	Potentially moderate to high	Variable absorption and diversion
Long-acting formulation	High theoretical value	High development cost and safety risk
Combination product	Variable	Clinical proof and patent validity
Manufacturing technology license	Moderate	Narrow claims and limited bargaining power

Licensing opportunities are most credible where a company owns a delivery platform, device, depot technology, or clinical dataset. A license based only on generic ketamine hydrochloride supply is unlikely to command durable economics.

Key Takeaways

• Ketamine hydrochloride is an old, generic active ingredient with no meaningful remaining composition-of-matter exclusivity.
• Conventional IV and IM injections are primarily a supply, quality, packaging, and contracting business.
• Preservative-free and ready-to-administer injectables offer practical but limited differentiation.
• Intranasal, buccal, sublingual, abuse-deterrent, and controlled-release products offer greater commercial upside.
• The strongest new patent claims will focus on delivery performance, devices, pharmacokinetics, manufacturing controls, or clinically differentiated use.
• Spravato and racemic ketamine are distinct products. Spravato’s regulatory and patent protections do not automatically block racemic ketamine.
• Schedule III controls, diversion risk, monitoring requirements, and psychiatric safety are central commercial constraints.
• A 505(b)(2) strategy may be appropriate for a novel route or formulation, but clinical differentiation remains necessary.
• Long-acting ketamine has the highest theoretical value and the highest development risk.
• The strongest near-term opportunity is a differentiated, reliable injectable or a tightly controlled nasal product with a defined clinical use.

FAQs About Ketamine Hydrochloride Excipient and Commercial Strategy

Can sodium chloride alone be used as the main excipient in ketamine hydrochloride injection?

Yes. Water for injection and sodium chloride are sufficient for a conventional aqueous isotonic formulation when pH, stability, sterility, and container compatibility are controlled.

Is benzethonium chloride appropriate for every ketamine formulation?

No. A preservative may be suitable for a particular multidose injectable presentation but should not be assumed appropriate for intranasal, neuraxial, pediatric, or other specialized routes.

Can a company patent a new ketamine hydrochloride concentration?

A concentration alone may be difficult to protect if it is an obvious optimization. Patent strength improves when the concentration produces an unexpected stability, dosing, safety, or pharmacokinetic result.

Would a ketamine nasal spray be automatically substitutable for Spravato?

No. Racemic ketamine nasal spray and esketamine nasal spray are different products. Substitution depends on FDA approval, labeling, dosage form, state law, payer policy, and clinical evidence.

Is a ketamine depot injection commercially realistic?

It is technically realistic but commercially demanding. The product must control burst release, allow consistent dosing, manage prolonged adverse effects, and demonstrate a meaningful benefit over supervised intermittent administration.

References

1. U.S. Food and Drug Administration. (2023). Ketalar (ketamine hydrochloride) injection prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). Spravato (esketamine hydrochloride) nasal spray prescribing information. FDA/DailyMed.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Drug Enforcement Administration. (2024). Controlled substances list: Ketamine. https://www.deadiversion.usdoj.gov/

5. National Library of Medicine. (2025). DailyMed: Ketamine hydrochloride injection product labeling. https://dailymed.nlm.nih.gov/

6. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2): Guidance for industry. FDA.